Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

735
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
735
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De-risking seizure liability: integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps.

Toxicological sciences : an official journal of the Society of Toxicology·2025
Same author

Artificial Intelligence and Machine Learning Models for Predicting Drug-Induced Kidney Injury in Small Molecules.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Safety Implications of Modulating Nuclear Receptors: A Comprehensive Analysis from Non-Clinical and Clinical Perspectives.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.

Frontiers in toxicology·2024
Same author

AI/ML Models to Predict the Severity of Drug-Induced Liver Injury for Small Molecules.

Chemical research in toxicology·2023
Same author

The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.

Regulatory toxicology and pharmacology : RTP·2021
Same journal

Environmental Concentrations of PFOS Accumulate in the <i>Euglena</i> Eyespot and Impair Chloroplast ATP Synthase Activity: A Dual Impairment of Phototaxis and Photosynthetic Light Reactions.

Toxics·2026
Same journal

Heavy Metal(loid) Pollution Characteristics and Risk Assessment in the Water-Soil-Vegetable System of a Watershed in Southwest China.

Toxics·2026
Same journal

Sludge Retention Time Governs Ectoine Synthesis and Pollutant Removal in Halophilic Activated Sludge Treating High-Salinity Wastewater.

Toxics·2026
Same journal

Interpretable Machine Learning and Spatiotemporal Modeling of Meteorological and Environmental Drivers for Tuberculosis Incidence in China.

Toxics·2026
Same journal

A 3D Graphene Oxide Model Reveals Fine Particulate Matter Induced Cell Cycle Dysregulation in Neural Stem Cells.

Toxics·2026
Same journal

Storage-Dependent Changes in Microplastic-Associated Recoverable Residues in Yogurt Containing <i>Bifidobacterium longum</i> subsp. <i>infantis</i>.

Toxics·2026
See all related articles

Related Experiment Video

Updated: Jul 12, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.6K

Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and

Mohan Rao1, Eric McDuffie1, Clifford Sachs1

  • 1Neurocrine Biosciences, Inc., Nonclinical Toxicology, San Diego, CA 92130, USA.

Toxics
|October 27, 2023
PubMed
Summary
This summary is machine-generated.

Drug discovery fails 90% of candidates. This study introduces a computational framework using AI/ML and chemical similarity to predict drug repurposing opportunities by identifying off-target interactions for approved small molecule drugs.

Keywords:
AI/MLcheminformaticsdrug life cycle managementdrug repurposingdue diligenceoff-target predictiontranscriptomics

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
11:58

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Published on: January 30, 2019

8.4K

Related Experiment Videos

Last Updated: Jul 12, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.6K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes
11:58

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Published on: January 30, 2019

8.4K

Area of Science:

  • Computational chemistry
  • Drug discovery and development
  • Pharmacology

Background:

  • Small molecule drug discovery faces high attrition rates (~90%) due to toxicity or efficacy issues.
  • Approved drugs interact with multiple targets (6-11 on average), suggesting repurposing potential.
  • Leveraging off-target interactions can uncover new therapeutic applications for existing compounds.

Purpose of the Study:

  • To develop and validate a computational framework for small molecule drug repurposing.
  • To identify novel off-target interactions for FDA-approved drugs.
  • To explore potential new therapeutic applications based on predicted drug-target interactions.

Main Methods:

  • Integrated artificial intelligence/machine learning (AI/ML) and chemical similarity approaches.
  • Employed eight distinct target prediction methods, including three machine learning models.
  • Analyzed a dataset of 2766 FDA-approved drugs and cross-species transcriptomics data.

Main Results:

  • Identified 27,371 off-target interactions across 2013 protein targets for 2766 drugs.
  • Found 150,620 structurally similar compounds to the drugs in the dataset.
  • Confirmed 63% (17,283) of predicted off-target interactions in vitro, with many showing high affinity (IC50 < 100 nM or < 10 nM).
  • GPCRs, enzymes, and kinases were the most frequent target classes for predicted interactions.

Conclusions:

  • The computational framework effectively predicts numerous off-target interactions for drug repurposing.
  • Validated interactions and tissue-specific expression patterns provide a basis for exploring new therapeutic uses of approved drugs.
  • This approach offers a promising strategy to overcome drug discovery attrition and accelerate the development of new treatments.